Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yunpi Jiedu Tongdu granule is a Traditional Chinese Medicine (TCM) herbal formulation developed by Zhejiang Chinese Medicine University for the treatment of undifferentiated spondyloarthritis (uSpA). The name reflects its therapeutic aims in TCM theory: 'Yunpi' (transporting/invigorating the spleen), 'Jiedu' (detoxifying), and 'Tongdu' (unblocking the Du meridian). It is currently being evaluated in clinical trials as an add-on therapy to non-steroidal anti-inflammatory drugs (NSAIDs) like meloxicam. The goal of treatment is to alleviate clinical symptoms, reduce inflammatory markers, and prevent the progression of undifferentiated cases into classified spondyloarthritis, such as ankylosing spondylitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yunpi Jiedu Tongdu granule.